<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mizuno T</submitter><funding>Research Center for Pathogenesis of Intractable Diseases, Research Institute of Meijo University</funding><funding>Ministry of Education, Culture, Science, and Technology</funding><funding>Japan Society for the Promotion of Science</funding><pagination>574-583</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10988669</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(4)</volume><pubmed_abstract>Acute lung injury (ALI), which occurs in association with sepsis, trauma, and coronavirus disease 2019 (COVID-19), is a serious clinical condition with high mortality. Excessive platelet-leukocyte aggregate (PLA) formation promotes neutrophil extracellular trap (NET) release and thrombosis, which are involved in various diseases, including ALI. Macrophage-1 antigen (Mac-1, CD11b/CD18), which is expressed on the surface of leukocytes, is known to promote NET formation. This study aimed to elucidate the role of Mac-1 in extracellular histone-induced ALI. Exogenous histones were administered to Mac-1-deficient mice and wild-type (WT) mice with or without neutrophil or platelet depletion, and several parameters were investigated 1 h after histone injection. Depletion of neutrophils or platelets improved survival time and macroscopic and microscopic properties of lung tissues, and decreased platelet-leukocyte formation and plasma myeloperoxidase levels. These improvements were also observed in Mac-1&lt;sup>-/-&lt;/sup> mice. NET formation in Mac-1&lt;sup>-/-&lt;/sup> bone marrow neutrophils (BMNs) was significantly lower than that in WT BMNs. In conclusion, our findings suggest that Mac-1 is associated with exacerbation of histone-induced ALI and the promotion of NET formation in the presence of activated platelets.</pubmed_abstract><journal>FEBS open bio</journal><pubmed_title>Macrophage-1 antigen exacerbates histone-induced acute lung injury and promotes neutrophil extracellular trap formation.</pubmed_title><pmcid>PMC10988669</pmcid><funding_grant_id>19K07232</funding_grant_id><funding_grant_id>21K06696</funding_grant_id><funding_grant_id>20J22610</funding_grant_id><pubmed_authors>Mizuno T</pubmed_authors><pubmed_authors>Nagano F</pubmed_authors><pubmed_authors>Fruhashi K</pubmed_authors><pubmed_authors>Yamada S</pubmed_authors><pubmed_authors>Tsuboi N</pubmed_authors><pubmed_authors>Takahashi K</pubmed_authors><pubmed_authors>Maruyama S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Macrophage-1 antigen exacerbates histone-induced acute lung injury and promotes neutrophil extracellular trap formation.</name><description>Acute lung injury (ALI), which occurs in association with sepsis, trauma, and coronavirus disease 2019 (COVID-19), is a serious clinical condition with high mortality. Excessive platelet-leukocyte aggregate (PLA) formation promotes neutrophil extracellular trap (NET) release and thrombosis, which are involved in various diseases, including ALI. Macrophage-1 antigen (Mac-1, CD11b/CD18), which is expressed on the surface of leukocytes, is known to promote NET formation. This study aimed to elucidate the role of Mac-1 in extracellular histone-induced ALI. Exogenous histones were administered to Mac-1-deficient mice and wild-type (WT) mice with or without neutrophil or platelet depletion, and several parameters were investigated 1 h after histone injection. Depletion of neutrophils or platelets improved survival time and macroscopic and microscopic properties of lung tissues, and decreased platelet-leukocyte formation and plasma myeloperoxidase levels. These improvements were also observed in Mac-1&lt;sup>-/-&lt;/sup> mice. NET formation in Mac-1&lt;sup>-/-&lt;/sup> bone marrow neutrophils (BMNs) was significantly lower than that in WT BMNs. In conclusion, our findings suggest that Mac-1 is associated with exacerbation of histone-induced ALI and the promotion of NET formation in the presence of activated platelets.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Apr</publication><modification>2025-04-18T20:13:30.768Z</modification><creation>2025-04-07T08:07:17.189Z</creation></dates><accession>S-EPMC10988669</accession><cross_references><pubmed>38360057</pubmed><doi>10.1002/2211-5463.13779</doi></cross_references></HashMap>